• Liraglutide (brand name Victoza) has demonstrated significant dose-dependent weight loss in studies of patients with type 2 diabetes mellitus (T2DM) which led to its investigation and in 2014 approval for the treatment of obesity (Saxenda).

Dosage

Patients with obesity now require to titrate up Liraglutide starting with 0.6mg then 1.2mg, 1.8 mg, 2.4 mg, 3.0 mg

Side Effects

  • The most frequent drug-related adverse events are mild to moderate, transient nausea and vomiting.

 

Mechanism of Action

 

 

  • Liraglutide is a glucagon-like peptide receptor (GLP-1R) agonists mimic GLP-1, an incretin gut hormone secreted when a meal is ingested.
  • GLP-1 lowers glucose by increasing insulin output and decreasing glucagon secretion, both in a glucose-dependent manner.
  • GLP-1Rs are expressed in the periphery and in several areas in the brain that are implicated in the regulation of appetite.

In my opinion, the inventors of this medicine class deserve a Nobel prize! Dr. Moe

 

Note: Saxenda is a very expensive medicine ($$$)

check out if Saxenda is covered by your insurance, follow the link below:

https://www.novocare.com/saxenda/check-coverage